REFERENCES
- Andersson T., Cederberg C., Edvardsson G., Heggelund A., Lundborg P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin. Pharmacol. Ther. 1990; 47: 79–85, [PUBMED], [INFOTRIEVE], [CSA]
- Andersson T., Flockhart D. A., Goldstein D. B., Huang S.-M., Kroetz D. L., Milos P. M., Ratain M. J., Thummel K. Drug Metabolizing Enzymes-Evidence for Clinical Utility of Pharmacogenomic Tests. Clin. Pharmacol. Ther 2005; 78(6)559–581, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Andersson T. “Special consideration of individual metabolic biomarkers: CYP2C19”. Presentation at the FDA/PhRMA/JHU educational workshop, Rockville, MD, September, 13–142004, http://www.fda.gov/cder/offices/ocpb/workshops.htm [accessed June 2, 2005]
- Blaisdell J., Mohrenweiser H., Jackson J., Ferguson S., Coulter S., Chanas B., Xi T., Ghanayem B., Goldstein J. A. Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 2002; 12: 703–711, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Chasman D. I., Posada D., Subrahmanyan L., Cook N. R., Stanton V. P., Jr, Ridker P. M. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004; 291: 2821–2827, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Cross J., Lee H., Westelinck A., Nelson J., Grudzinskas C., Peck C. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980–1999. Pharmacoepidemiol. Drug Saf. 2002; 11: 439–446, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Dai D., Tang J., Rose R., Hodgson E., Bienstock R. J., Mohrenweiser H. W., Goldstein J. A. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J. Pharmacol. Exp. Ther. 2001; 299: 825–831, [PUBMED], [INFOTRIEVE], [CSA]
- DIA/FDA workshop: Co-Development of Drug. Biological and Device Products. Arlington, Washington, VA. DC, July, 292004. U.S. Food and Drug Administration/Horsham, Drug Information Association, PA, Available: http://www.diahome.org/Content/Events/04040.pdf [accessed August 31 2004].
- Eckhardt K., Li S., Ammon S., Schanzle G., Mikus G., Eichelbaum M. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 1998; 76: 27–33, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Evans W. E., Relling M. V. Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics. Science 1999; 286: 487–491, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Evans W. E., Hon Y. Y., Bomgaars L., Coutre S., Holdsworth M., Janco R., Kalwinsky D., Keller F., Khatib Z., Margolin J., Murray J., Quinn J., Ravindranath Y., Ritchey K., Roberts W., Rogers Z. R., Schiff D., Steuber C., Tucci F., Kornegay N., Krynetski E. Y., Relling M. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J. Clin. Oncol. 2001; 19: 2293–2301, [PUBMED], [INFOTRIEVE], [CSA]
- Evans W. E., McLeod H. L. Pharmacogenomics–drug disposition, drug targets, and side effects. N. Engl. J. Med. 2003; 348: 538–549, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Evans W. E., Relling M. V. Moving towards individualized medicine with pharmacogenomics. Nature 2004; 429: 464–468, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Evans W. E. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther. Drug. Monit. 2004; 26: 186–191, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- FDA MAPP: Clinical Pharmacology and Biopharmaceutics NDA Review Template, (Issued 4/27/2004, Posted 6/24/2004): http://www.fda.gov/cder/mapp/4000.4.pdf (last accessed August 31, 2004)
- Food and Drug Administration (FDA) strategic plan: FDA Commissioner. 2003, McClellan, MB, FDA Strategic Action Plan; August: http://www.fda.gov/oc/mcclellan/strategic.html.
- FDA Advisory Committee for Pharmaceutical Sciences. Clinical Pharmacology Subcommittee meeting. 2005, http://www.fda.gov/ohrms/dockets/ac/cder05.html#PharmSciencelabeling recommendations: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4194B103Topic-1A.pdf http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4194S1Slide-Index.htm; http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4194S10201-Huang.ppt
- FDA CDER/CBER Guidance for Industry: Exposure-Response Relationships-Study Design. Data Analysis, and Regulatory Applications, http://www.fda.gov/cder/guidance/5341fnl.pdf, May 2003
- FDA Mission Statement. 2004, http://www.fda.gov/opacom/morechoices/mmission.html [accessed September 4, 2004]
- FDA whitepaper. Innovation or Stagnation, challenge and opportunity on the critical path to new medical products. 2004, http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html [accessed September 4 2004]
- FDA CDER/CBER/CDRH Guidance for industry: Pharmacogenomic data submission, posted on March 22, 2005: http://www.fda.gov/cder/guidance/6400fnl.pdf [accessed March 25, 2005]
- FDA CDER/CBER/CDRH Guidance for industry: Pharmacogenomic data submission, Examples of Voluntary Submissions or Submissions Required Under 21 CFR 312, 314, or 601, posted on March 22, 2005: http://www.fda.gov/cder/guidance/6400fnlAttch.pdf [accessed March 25, 2005]
- FDA Labeling information from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda, http://www.fda.gov/cder/approval/index.htm, http://pdrel.thomsonhc.com/pdrel/librarian or Physicians' Desk Reference at
- FDA Purinenthol labeling, http://www.fda.gov/cder/foi/label/2004/09053s024lbl.pdf [last accessed September 18, 2004]
- FDA Atomoxetine clinical pharmacology review, http://www.fda.gov/cder/foi/nda/2002/21-411_Strattera_biopharmr_P1.pdf2002
- FDA, CDRH Guidance for Industry and FDA Staff. Class II Special Controls Guidance Document: Instrumentation for Clinical Multiplex Test Systems, http://www.fda.gov/cdrh/oivd/guidance/1546.html, March, 2005
- FDA CDRH Guidance for Industry and FDA Staff. Class II Special Controls Guidance Document: Drug Metabolizing Enzyme Genotyping System, http://www.fda.gov/cdrh/oivd/guidance/1551.html, March, 2005
- FDA Drug-diagnostic co-development concept paper. April, 2005, http://www.fda.gov/cder/genomics/pharmacoconceptfn.pdf [accessed April 22, 2005]
- FDA Draft guidance for industry Labeling for Human Prescription Drug and Biological Products—Implementing the New Content and Format Requirements, http://www.fda.gov/cder/guidance/6005dft.pdf[accessed January 21, 2006]
- FDA workshop: FDA/PhRMA/JHU educational workshop. Rockville, MD, September, 13–142004, http://www.fda.gov/cder/offices/ocpb/workshops.htm [accessed June 2, 2005]
- FR notice 2000: Labeling guideline, (Federal Register 65: 247; 81082–81131; December 22, 2000)
- Fellay J., Marzolini C., Meaden E. R., Back D. J., Buclin T., Chave J. P., Decosterd L. A., Furrer H., Opravil M., Pantaleo G., Retelska D., Ruiz L., Schinkel A. H., Vernazza P., Eap C. B., Telenti A. Swiss HIV Cohort Study, Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study. Lancet. 2002; 359: 30–36, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Flockhart D. “Special consideration of individual metabolic biomarkers: CYP2D6” presentation at the FDA/PhRMA/JHU educational workshop. Rockville, MD, September, 13–142004, http://www.fda.gov/cder/offices/ocpb/workshops.htm [accessed June 2, 2005]
- Frueh F. W., Huang S.-M., Lesko L. J. 112-12 editorial: Regulatory acceptance of toxicogenomics data. Environ. Health Perspect 2004; 112: A663–A664, [PUBMED], [INFOTRIEVE], [CSA]
- Frueh F. W., Goodsaid F., Rudman A., Huang S.-M., Lesko L. J. The Need for Education in Pharmacogenomics: A regulatory perspective. Pharmacogenomics J. 2005; 5: 218–220, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Furman K. D., Grimm D. R., Mueller T., Holley-Shanks R. R., Bertz R. J., Williams L. A., Spear B. B., Katz D. A. Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics. Pharmacogenetics 2004; 14: 279–284, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Furuta T., Shirai N., Sugimoto M., Ohashi K., Ishizaki T. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2004; 5: 181–202, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gaedigk A., Bradford L. D., Marcucci K. A., Leeder J. S. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin. Pharmacol. Ther. 2002; 72: 76–89, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Goodsaid F., Huang S.-M., Frueh F., Temple R., Lesko L. J. Regulatory Guidance and Application of Genomic Biomarkers in Drug Development in “Principles of Clinical Pharmacogenomics,”, H Steven, Y. Wong, Mark Linder, Roland Valdes. AACC Press, (in press)
- Hamelin B. A., Bouayad A., Methot J., Jobin J., Desgagnes P., Poirier P., Allaire J., Dumesnil J., Turgeon J. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin. Pharmacol. Ther. 2000; 67: 466–477, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Haufroid V., Mourad M., Van Kerckhove V., Wawrzyniak J., De Meyer M., Eddour D. C., Malaise J., Lison D., Squifflet J. P., Wallemacq P. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147–154, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hetherington S., Hughes A. R., Mosteller M., Shortino D., Baker K. L., Spreen W., Lai E., Davies K., Handley A., Dow D. J., Fling M. E., Stocum M., Bowman C., Thurmond L. M., Roses A. D. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359: 1121–1122, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Higashi M. K., Veenstra D. L., Kondo L. M., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690–1698, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- HIll M. A., Wilke R. A., Caldwell M. D., Berg R. L., Glurich I., Burmester J. K. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 2004; 4: 539–547, [CSA]
- Hoffmeyer S., Burk O., von Richter O., Arnold H. P., Brockmoller J., Johne A., Cascorbi I., Gerloff T., Roots I., Eichelbaum M., Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 2000; 97: 3473–3478, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Huang S.-M., Miller M., Toigo T., Chen M., Sahajwalla C., Lesko L. J., Temple R. Evaluation of Drugs in Women: Regulatory Perspective—in Section 11, Drug Metabolism/Clinical pharmacology (section editor: Schwartz, J). “Principles of Gender-Specific Medicine,”, M Legato. Academic Press. 2004; 848–859
- Huang S.-M., Lesko L. J. Drug-drug, drug-dietary supplement and drug-citrus fruit and other food interactions- what have we learned?. J. Clin. Pharmacol. 2004; 44: 559–569, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Huang S.-M. “Regulatory issues in genotyping metabolizing enzymes- CDER Perspective”. presentation at the FDA/PhRMA/JHU educational workshop, Rockville, MD, September, 13-142004, http://www.fda.gov/cder/offices/ocpb/workshops.htm [accessed June 2, 2005]
- Huang S.-M., Lesko L. J. Application of Pharmacogenomics in Clinical Pharmacology—in Volume I: Molecular Medicine, Correlation between genes, diseases and biopharmaceuticals. “Modern Biopharmaceuticals- Design, Development and Optimization”, Jorg Knablein, R H Muller. Wiley, VCH 2005; 49–70
- Human cytochrome P450 (CYP) nomenclature committee web http://www.imm.ki.se/cypalleles/ [last accessed September 4, 2004]
- ICH E5. Guidance on Ethnic Factors in the Acceptability of Foreign Clinical Data. 1998, http://www.fda.gov/cder/guidance/index.htm, http://www.fda.gov/cder/guidance/6200fnl.pdf [accessed September 4, 2004], E5 Questions and Answers (2004)
- Innocenti F., Undevia S. D., Iyer L., Chen P. X., Das S., Kocherginsky M., Karrison T., Janisch L., Ramirez J., Rudin C. M., Vokes E. E., Ratain M. J. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 2004; 22: 1382–1388, Epub 2004 Mar 08[PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Israel E., Drazen J. M., Liggett S. B., Boushey H. A., Cherniack R. M., Chinchilli V. M., Cooper D. M., Fahy J. V., Fish J. E., Ford J. G., Kraft M., Kunselman S., Lazarus S. C., Lemanske R. F., Jr, Martin R. J., McLean D. E., Peters S. P., Silverman E. K., Sorkness C. A., Szefler S. J., Weiss S. T., Yandava C. N. National Heart, Lung, and Blood Institute's Asthma Clinical Research Network, Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma. Int. J. Arch. Allergy Immunol. 2001; 124: 183–186, [CROSSREF], [CSA]
- Iyer L., Das S., Janisch L., Wen M., Ramirez J., Karrison T., Fleming G. F., Vokes E. E., Schilsky R. L., Ratain M. J. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002; 2: 43–47, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kim R. B., Leake B. F., Choo E. F., Dresser G. K., Kubba S. V., Schwarz U. I., Taylor A., Xie H. G., McKinsey J., Zhou S., Lan L. B., Schuetz J. D., Schuetz E. G., Wilkinson G. R. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 2001; 70: 189–199, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lazarou J., Pomeranz B. H., Corey P. N. Incidence of Adverse Drug Reactions in Hospitalized Patients, A Meta-analysis of Prospective Studies. JAMA 1998; 279: 1200–1205, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lesko L. J., Salerno R. A., Spear B. B., Anderson D. C., Anderson T., Brazell C., Collins J., Dorner A., Essayan D., Gomez-Mancilla B., Hackett J., Huang S. M., Ide S., Killinger J., Leighton J., Mansfield E., Meyer R., Ryan S. G., Schmith V., Shaw P., Sistare F., Watson M., Worobec A. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop. J. Clin. Pharmacol. 2003; 43: 342–358, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Leighton J. K., DeGeorge J., Jacobson-Kram D., MacGregor J., Mendrick D., Worobec A. Pharmacogenomic data submissions to the FDA: non-clinical case studies. Pharmacogenomics 2004; 5: 507–511, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lesko L. J., Woodcock J. Translation of pharmacogenomics and pharmacogenetics: A regulatory perspective. Nat. Rev. Drug Discov. 2004; 3: 763–769, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Liou Y. J., Wang Y. C., Bai Y. M., Lin C. C., Yu S. C., Liao D. L., Lin M. W., Chen J. Y., Lai I. C. Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2004; 49: 167–173, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Louis E., El Ghoul Z., Vermeire S., Dall'Ozzo S., Rutgeerts P., Paintaud G., Belaiche J., De Vos M., Van Gossum A., Colombel J. F., Watier H. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment. Pharmacol. Ther. 2004; 19: 511–519, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lynch T. J., Bell D. W., Sordella R., Gurubhagavatula S., Okimoto R. A., Brannigan B. W., Harris P. L., Haserlat S. M., Supko J. G., Haluska F. G., Louis D. N., Christiani D. C., Settleman J., Haber D. A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004; 350: 2129–2139, Epub 2004 Apr 29[PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Milos P. “Special consideration of individual metabolic biomarkers: CYP2C9”. Presentation at the FDA/PhRMA/JHU educational workshop, Rockville, MD, September, 13-142004, http://www.fda.gov/cder/offices/ocpb/workshops.htm [accessed June 2, 2005].
- McLeod H. L., Krynetski E. Y., Relling M. V., Evans W. E. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia. 2000; 14: 567–572, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Niemi M., Leathart J. B., Neuvonen M., Backman J. T., Daly A. K., Neuvonen P. J. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin. Pharmacol. Ther. 2003; 74: 380–387, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Nishizato Y., Ieiri I., Suzuki H., Kimura M., Kawabata K., Hirota T., Takane H., Irie S., Kusuhara H., Urasaki Y., Urae A., Higuchi S., Otsubo K., Sugiyama Y. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 2003; 73: 554–565, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Otterness D., Szumlanski C., Lennard L., Klemetsdal B., Aarbakke J., Park-Hah J. O., Iven H., Schmiegelow K., Branum E., O'Brien J., Weinshilboum R. Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms. Clin. Pharmacol. Ther. 1997; 62: 60–73, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Priori S. G., Napolitano C., Schwartz P. J., Grillo M., Bloise R., Ronchetti E., Moncalvo C., Tulipani C., Veia A., Bottelli G., Nastoli J. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 2004; 292: 1341–1344, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Phillips K. A., Veenstra D. L., Oren E., Lee J. K., Sadee W. Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: A Systematic Review. JAMA 2001; 286: 2270–2279, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Pauli-Magnus C., Kroetz D. L. Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm. Res. 2004; 21: 904–913, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Peyvandi F., Spreafico M., Siboni S. M., Moia M., Mannucci P. M. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin. Pharmacol. Ther. 2004; 75: 198–203, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ratain M. “Special consideration of individual metabolic biomarkers: UGT1A1”. presentation at the FDA/PhRMA/JHU educational workshop, Rockville, MD, September, 13–142004, http://www.fda.gov/cder/offices/ocpb/workshops.htm
- Rouits E., Boisdron-Celle M., Dumont A., Guerin O., Morel A., Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: A molecular and clinical study of 75 patients. Clin. Cancer Res. 2004; 10: 5151–5159, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ruaño G., Collins J. M., Dorner A. J., Wang S.-J., Guerciolini R., Huang S.-M. Pharmacogenomic data submissions to the FDA: Clinical pharmacology case studies. Pharmacogenomics 2004; 5: 513–517, [CROSSREF], [CSA]
- Ruano G., et al. XIV International Symposium on Drugs Affecting Lipid Metabolism. Abstract in 52nd Annual American College of Cardiology (Scientific Session), Chicago, IL, March-April, 30-22003, July 12, 2003
- Sai K., Saeki M., Saito Y., Ozawa S., Katori N., Jinno H., Hasegawa R., Kaniwa N., Sawada J., Komamura K., Ueno K., Kamakura S., Kitakaze M., Kitamura Y., Kamatani N., Minami H., Ohtsu A., Shirao K., Yoshida T., Saijo N. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin. Pharmacol. Ther. 2004; 75: 501–515, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Salerno R. A., Lesko L. J. Pharmacogenomic data: FDA voluntary and required submission guidance. Pharmacogenomics 2004a; 5: 503–505, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Salerno R. A., Lesko L. J. Pharmacogenomics in drug development and regulatory decision-making: The Genomic Data Submission (GDS) proposal. Pharmacogenomics 2004b; 5: 25–30, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sai K., Saeki M., Saito Y., Ozawa S., Katori N., Jinno H., Hasegawa R., Kaniwa N., Sawada J., Komamura K., Ueno K., Kamakura S., Kitakaze M., Kitamura Y., Kamatani N., Minami H., Ohtsu A., Shirao K., Yoshida T., Saijo N. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin. Pharmacol. Ther. 2004; 75: 501–515, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Siddiqui A., Kerb R., Weale M. E., Brinkmann U., Smith A., Goldstein D. B., Wood N. W., Sisodiya S. M. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB. N. Engl. J. Med. 2003; 348: 1442–1448, [PUBMED], [INFOTRIEVE], [CSA]
- Stearns V., Johnson M. D., Rae J. M., Morocho A., Novielli A., Bhargava P., Hayes D. F., Desta Z., Flockhart D. A. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 2003; 95: 1758–1764, [PUBMED], [INFOTRIEVE], [CSA]
- Temple R. J., Cross J., Lee H., Westelinck A., Nelson J., Grudzinskas C., Peck C. Defining dose decrease. Comment on Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980–1999. Pharmacoepidemiol. Drug Saf. 2002; 11: 439–46, [CROSSREF], [CSA]
- Pharmacoepidemiol. Drug Saf. 2003; 12: 151–152, [CROSSREF], [CSA]
- Thorn C. F., Carrillo M. W., Ramirez J., Marsh S., Schuetz E. G., Dolan M. E., Innocenti F., Relling M. V., McLeod H. L., Ratain M. J. Irinotecan pathway, http://www.pharmgkb.org/search/pathway/irinotecan/liver.jsp, last updated March 10, 2005
- Trepicchio W. L., Williams G. A., Essayan D., Hall S. T., Harty L. C., Shaw P. M., et al. Pharmacogenomic data submissions to the FDA: Clinical case studies. Pharmacogenomics 2004; 5: 519–524, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tsuchiya K., Gatanaga H., Tachikawa N., Teruya K., Kikuchi Y., Yoshino M., Kuwahara T., Shirasaka T., Kimura S., Oka S. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem. Biophys. Res. Commun. 2004; 319(4)1322–1326, Jul 9[PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wan Y. J., Poland R. E., Han G., Konishi T., Zheng Y. P., Berman N., Lin K. M. Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California. Pharmacogenetics 2001; 11: 489–499, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Weinshilboum R. Inheritance and drug response. N. Engl. J. Med. 2003; 348: 529–537, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Weinshilboum R. Thiopurine pharmacogenetics: Clinical and molecular studies of thiopurine methyltransferase. Drug. Metab. Dispos. 2001; 29(4 Pt 2) 601–605, [PUBMED], [INFOTRIEVE], [CSA]
- Weinshilboum R., Wang L. Pharmacogenomics: Bench to bedside. Nat. Rev. Drug Discov. 2004; 3: 739–748, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Xie H. G., Kim R. B., Wood A. J., Stein C. M. Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol. 2001; 41: 815–850, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Xu C., Rao Y. S., Xu B., Hoffmann E., Jones J., Sellers E. M., Tyndale R. F. An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem. Biophys. Res. Commun. 2002; 290: 318–324, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yang P., Kanki H., Drolet B., Yang T., Wei J., Viswanathan P. C., Hohnloser S. H., Shimizu W., Schwartz P. J., Stanton M., Murray K. T., Norris K., George A. L., Jr., Roden D. M. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002; 105: 1943–1948, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yasui-Furukori N., Takahata T., Nakagami T., Yoshiya G., Inoue Y., Kaneko S., Tateishi T. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br. J. Clin. Pharmacol. 2004; 57: 487–494, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yin O. Q.P., Tomlinson B., Waye M. M. Y., Chow A. H. L., Chow M. S. S. Pharmacogenetics and herb–drug interactions: Experience with Ginkgo bilobaand omeprazole. Pharmacogenetics, (in press)[CSA]
- Zheng H., Zeevi A., Schuetz E., Lamba J., McCurry K., Griffith B. P., Webber S., Ristich J., Dauber J., Iacono A., Grgurich W., Zaldonis D., McDade K., Zhang J., Burckart G. J. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J. Clin. Pharmacol. 2004; 44: 135–140, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Zheng H. X., Burckart G. J., McCurry K., Webber S., Ristich J., Iacono A., Dauber J., McDade K., Grgurich W., Zaldonis D., Pillage G., Griffith B. P., Zeevi A. Interleukin-10 production genotype protects against acute persistent rejection after lung transplantation. J. Heart Lung Transplant. 2004; 23: 541–546, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]